JP2009510134A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009510134A5 JP2009510134A5 JP2008533837A JP2008533837A JP2009510134A5 JP 2009510134 A5 JP2009510134 A5 JP 2009510134A5 JP 2008533837 A JP2008533837 A JP 2008533837A JP 2008533837 A JP2008533837 A JP 2008533837A JP 2009510134 A5 JP2009510134 A5 JP 2009510134A5
- Authority
- JP
- Japan
- Prior art keywords
- gastrin
- pharmaceutical composition
- seq
- composition according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72491905P | 2005-10-07 | 2005-10-07 | |
| PCT/CA2006/001644 WO2007041833A1 (en) | 2005-10-07 | 2006-10-06 | Combined use of dpp iv inhibitors and gastrin compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009510134A JP2009510134A (ja) | 2009-03-12 |
| JP2009510134A5 true JP2009510134A5 (enExample) | 2009-09-24 |
Family
ID=37942251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008533837A Withdrawn JP2009510134A (ja) | 2005-10-07 | 2006-10-06 | Ｄｐｐ−ｉｖ阻害剤およびガストリン化合物の組み合わせ使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20100144613A1 (enExample) |
| EP (1) | EP1951286A4 (enExample) |
| JP (1) | JP2009510134A (enExample) |
| CN (1) | CN101365476A (enExample) |
| AU (1) | AU2006301892A1 (enExample) |
| BR (1) | BRPI0616949A2 (enExample) |
| CA (1) | CA2625150A1 (enExample) |
| WO (1) | WO2007041833A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1486204A (zh) | 2001-01-12 | 2004-03-31 | ������˹ҩƷ��˾ | 用于胰岛再生的含胃泌素/cck受体配基及egf受体配基的组合物 |
| ATE375166T1 (de) | 2002-06-07 | 2007-10-15 | Waratah Pharmaceuticals Inc | Zusammensetzungen und verfahren zur behandlung von diabetes |
| EP1837031B1 (en) | 2002-06-07 | 2009-10-14 | Waratah Pharmaceuticals, Inc. | Compositions and methods for treating diabetes |
| WO2008098256A1 (en) * | 2007-02-09 | 2008-08-14 | Bristol-Myers Squibb Company | Methods for identifying patients with an increased likelihood of responding to dpp-iv inhibitors |
| AU2008297874A1 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of secretin and optionally urodilatin as therapeutic agents |
| CA2699177A1 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| WO2010079433A2 (en) * | 2009-01-07 | 2010-07-15 | Glenmark Pharmaceuticals, S.A. | Pharmaceutical composition that includes a dipeptidyl peptidase-iv inhibitor |
| US8808689B1 (en) * | 2012-09-27 | 2014-08-19 | Perle Bioscience, Inc. | Insulin independence among patients with diabetes utilizing a PPI in combination with an immune tolerance agent |
| CA3079081A1 (en) | 2017-10-19 | 2019-04-25 | Michael D. Bartberger | Benzimidazole derivatives and their uses |
| MA54619A (fr) * | 2018-12-28 | 2021-11-03 | Mitsubishi Tanabe Pharma Corp | Cristal de composé d'acide pyrophosphorique |
| EP4376866A4 (en) * | 2021-06-10 | 2025-10-08 | Fouad Kandeel | COMPOSITIONS AND METHODS FOR ISLET OF LANGERHANS TRANSPLANTS |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6558952B1 (en) * | 1992-12-14 | 2003-05-06 | Waratah Pharmaceuticals, Inc. | Treatment for diabetes |
| US5885956A (en) * | 1992-12-14 | 1999-03-23 | Research Triangle Pharmaceuticals | Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand |
| GB9409496D0 (en) * | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
| US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| US20040037818A1 (en) * | 1998-07-30 | 2004-02-26 | Brand Stephen J. | Treatment for diabetes |
| CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| EP1741445B1 (en) * | 2000-01-21 | 2013-08-14 | Novartis AG | Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents |
| WO2001072290A2 (en) * | 2000-03-31 | 2001-10-04 | Probiodrug Ag | Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
| CN1486204A (zh) * | 2001-01-12 | 2004-03-31 | ������˹ҩƷ��˾ | 用于胰岛再生的含胃泌素/cck受体配基及egf受体配基的组合物 |
| US7202080B2 (en) * | 2001-03-29 | 2007-04-10 | Ixion Biotechnology, Inc. | Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway |
| US7037504B2 (en) * | 2001-10-23 | 2006-05-02 | Waratah Pharmaceuticals, Inc. | Epidermal growth factor protein and gene, and methods of use therefor |
| CA2494134A1 (en) * | 2002-05-24 | 2003-12-04 | Waratah Pharmaceuticals, Inc. | Treatment for diabetes |
| EP1837031B1 (en) * | 2002-06-07 | 2009-10-14 | Waratah Pharmaceuticals, Inc. | Compositions and methods for treating diabetes |
| ATE375166T1 (de) * | 2002-06-07 | 2007-10-15 | Waratah Pharmaceuticals Inc | Zusammensetzungen und verfahren zur behandlung von diabetes |
| JP2006506386A (ja) * | 2002-10-22 | 2006-02-23 | ワラタ ファーマシューティカルズ， インコーポレイテッド | 糖尿病の処置 |
| US20040229810A1 (en) * | 2002-10-22 | 2004-11-18 | Antonio Cruz | Gastrin compositions and formulations, and methods of use and preparation |
| BRPI0507189A (pt) * | 2004-01-30 | 2007-06-26 | Waratah Pharmaceuticals Inc | uso combinado de um agonista de glp-1 e compostos de gastrina |
-
2006
- 2006-10-06 AU AU2006301892A patent/AU2006301892A1/en not_active Abandoned
- 2006-10-06 JP JP2008533837A patent/JP2009510134A/ja not_active Withdrawn
- 2006-10-06 US US12/083,175 patent/US20100144613A1/en not_active Abandoned
- 2006-10-06 US US11/545,025 patent/US20090054314A1/en not_active Abandoned
- 2006-10-06 CN CNA2006800458916A patent/CN101365476A/zh active Pending
- 2006-10-06 BR BRPI0616949-0A patent/BRPI0616949A2/pt not_active IP Right Cessation
- 2006-10-06 CA CA002625150A patent/CA2625150A1/en not_active Abandoned
- 2006-10-06 EP EP06790802A patent/EP1951286A4/en not_active Withdrawn
- 2006-10-06 WO PCT/CA2006/001644 patent/WO2007041833A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013155195A5 (enExample) | ||
| JP2009538348A5 (enExample) | ||
| WO2009076173A3 (en) | Fluorinated tripeptide hcv serine protease inhibitors | |
| WO2008131149A3 (en) | Crystal forms of saxagliptin and processes for preparing same | |
| JP2009510134A5 (enExample) | ||
| EP2368900A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| WO2008019266A3 (en) | Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors | |
| TW200400199A (en) | Hepatitis C inhibitor tri-peptides | |
| WO2008021733A3 (en) | Tetrazolyl acyclic hepatitis c serine protease inhibitors | |
| WO2005028501A1 (en) | Macrocyclic peptides active against the hepatitis c virus | |
| WO2008022006A3 (en) | Arylalkoxyl hepatitis c virus protease inhibitors | |
| WO2007143694A3 (en) | Macrocyclic oximyl hepatitis c protease inhibitors | |
| WO2009076166A3 (en) | Oximyl hcv serine protease inhibitors | |
| WO2008021871A3 (en) | Triazolyl acyclic hepatitis c serine protease inhibitors | |
| JP2013503862A5 (enExample) | ||
| WO2011080102A3 (en) | Glp-1 analogues and derivatives | |
| WO2009053828A3 (en) | P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors | |
| JP2010505831A5 (enExample) | ||
| WO2008021956A3 (en) | Acylaminoheteroaryl hepatitis c virus protease inhibitors | |
| WO2007096662A3 (en) | Cancer imaging and treatment | |
| JP2010536714A5 (enExample) | ||
| WO2008069917A3 (en) | Novel cyclic peptides | |
| JP2006514104A5 (enExample) | ||
| JP2006506942A5 (enExample) | ||
| JP2010513327A5 (enExample) |